SIUE School of Pharmacy appoints Lubsch to lead Pediatric Pharmacy initiative
EDWARDSVILLE, Ill. — The Southern Illinois University Edwardsville School of Pharmacy’s Lisa Lubsch has been appointed to lead the Pediatric Pharmacy Advocacy Group-University initiative.
SIUE’s Lisa Lubsch, clinical associate professor of pharmacy practice in the School of Pharmacy, with a patient.
As part of her role beginning in spring 2015, Lubsch will direct section leaders from 15 areas of expertise in the field of pediatric pharmacy. “I have had the pleasure and honor working my way through the ranks of the Pediatric Pharmacy Advocacy Group, which has been an integral part of my professional development,” stated Lubsch, a clinical associate professor of pharmacy practice. “I am thrilled to be developing the first programs of the PPAG-U and to see my pediatric colleagues become recognized by board certification in our specialty area as they improve the care of children across the country.”
The Pediatric Pharmacy Advocacy Group helps prepare for pediatric board certification through educational opportunities and programming. The newly created PPAG-U will be a central hub for educational courses, conferences, programs and information designed to support the educational goals of pediatric pharmacists.
“It is commendable that Dr. Lubsch has been recognized to head the PPAG-U initiative,” added Gireesh Gupchup, dean of the SIUE School of Pharmacy. “It is an indication that she is recognized nationally as a thought leader in the area of pediatric pharmacy.”
Publix rolls out med sync program chainwide, powered by Ateb’s Time My Meds
RALEIGH, N.C. — Publix Super Markets is rolling out their Time My Meds powered medication synchronization program, Sync Your Refills, to all of its pharmacy locations.
“As both a supermarket and pharmacy, we are focused on providing convenient programs and services to our customers,” stated Maria Brous, Publix media and community relations director. “Our Sync Your Refills program, powered by Ateb’s Time My Meds, is designed to respect the time of our customers and continue to build on a strong relationship between patient and pharmacist.”
“Publix innovation, customer focus, and a strong commitment to partnership have allowed Ateb to successfully and rapidly integrate Time My Meds for Publix,” added Debbie Sheppard, VP sales and marketing for Ateb. “More importantly, it is exciting to see how pharmacy organizations like Publix are working to bring new, innovative ways to help pharmacy teams to work closely with patients to address important healthcare issues. With all the challenges in health care today, Publix demonstrates how integral pharmacy can be in helping patients achieve their healthcare objectives.”
Publix utilizes Ateb’s Time My Meds solution to manage their Sync Your Refills program. Ateb’s Time My Meds solution automatically identifies eligible patients, guides the pharmacy through the patient enrollment process, manages the ongoing synchronization process and allows Publix to place automated calls or texts to patients with important prescription-ready reminders.
Ateb’s Time My Meds also provides key measurements and analytics that allow Publix to monitor and improve the program consistently across all pharmacies.
Publix recently completed testing the Sync Your Refills program in their Atlanta division and is now in the process of activating the program in all 925 Publix pharmacies.
FDA approves Mekinist in combination with Tafinlar to treat patients with advanced melanoma
NEW YORK — The Food and Drug Administration recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (i.e., cannot be removed by surgery) or metastatic (i.e., late-stage), Onco360 announced last week.
Both Mekinist and Tafinlar are only available in limited distribution, and Onco360 is one of the few pharmacies with access to both medications.
Mekinist and Tafinlar are used to block signaling in different sites of the same molecular pathway that promotes cancer cell growth. They are specifically indicated as a combination therapy for patients with melanoma whose tumors express gene mutations called BRAF V600E and V600K1. Clinical trial results for the combination therapy were highly encouraging.
Results showed that 76% of participants treated with Mekinist in combination with Tafinlar had their cancer shrink or disappear (objective response) that lasted an average of 10.5 months. In contrast, 54% of participants treated with Tafinlar as a single agent experienced objective responses that lasted an average of 5.6 months.
Clinical trials are ongoing to determine whether Mekinist in combination with Tafinlar improves survival.